Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 14 | 2021 | 426 | 2.450 |
Why?
|
| Breast Neoplasms | 36 | 2022 | 3022 | 2.430 |
Why?
|
| Carcinoma, Ductal, Breast | 9 | 2015 | 160 | 1.780 |
Why?
|
| Sentinel Lymph Node Biopsy | 10 | 2018 | 73 | 1.690 |
Why?
|
| Thyroidectomy | 11 | 2021 | 171 | 1.660 |
Why?
|
| Lymph Node Excision | 10 | 2018 | 220 | 1.640 |
Why?
|
| Mastectomy | 17 | 2022 | 246 | 1.630 |
Why?
|
| Lymph Nodes | 12 | 2018 | 550 | 1.590 |
Why?
|
| Carcinoma, Papillary | 8 | 2020 | 156 | 1.450 |
Why?
|
| Carcinoma, Lobular | 8 | 2015 | 81 | 1.440 |
Why?
|
| Mastectomy, Segmental | 7 | 2017 | 101 | 1.420 |
Why?
|
| Adrenocortical Carcinoma | 4 | 2022 | 11 | 1.280 |
Why?
|
| Adrenal Cortex Neoplasms | 4 | 2022 | 17 | 1.270 |
Why?
|
| Iodine Radioisotopes | 6 | 2021 | 134 | 1.270 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2016 | 117 | 1.190 |
Why?
|
| Carcinoma | 4 | 2017 | 438 | 0.950 |
Why?
|
| Parathyroidectomy | 3 | 2020 | 80 | 0.920 |
Why?
|
| Lymphatic Metastasis | 14 | 2020 | 495 | 0.880 |
Why?
|
| Hyperparathyroidism, Primary | 3 | 2020 | 45 | 0.800 |
Why?
|
| Radiopharmaceuticals | 4 | 2016 | 198 | 0.730 |
Why?
|
| Databases, Factual | 13 | 2020 | 866 | 0.690 |
Why?
|
| Axilla | 13 | 2018 | 103 | 0.680 |
Why?
|
| Hypercalcemia | 1 | 2018 | 63 | 0.610 |
Why?
|
| Neoplasm Staging | 16 | 2021 | 2000 | 0.590 |
Why?
|
| Middle Aged | 49 | 2021 | 26159 | 0.580 |
Why?
|
| Thyroid Gland | 6 | 2021 | 280 | 0.560 |
Why?
|
| Female | 57 | 2022 | 46602 | 0.520 |
Why?
|
| Aged | 39 | 2021 | 19262 | 0.520 |
Why?
|
| Guideline Adherence | 1 | 2015 | 234 | 0.430 |
Why?
|
| Humans | 63 | 2022 | 89985 | 0.430 |
Why?
|
| Surgeons | 3 | 2022 | 249 | 0.410 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2021 | 290 | 0.410 |
Why?
|
| Aged, 80 and over | 16 | 2021 | 6785 | 0.390 |
Why?
|
| Retrospective Studies | 19 | 2022 | 9216 | 0.390 |
Why?
|
| Prognosis | 17 | 2019 | 3800 | 0.390 |
Why?
|
| Adult | 31 | 2021 | 26827 | 0.380 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 608 | 0.330 |
Why?
|
| Combined Modality Therapy | 5 | 2022 | 1704 | 0.320 |
Why?
|
| Neck Dissection | 2 | 2021 | 67 | 0.310 |
Why?
|
| Nipples | 5 | 2022 | 37 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 1355 | 0.290 |
Why?
|
| Logistic Models | 5 | 2020 | 1214 | 0.280 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 3678 | 0.280 |
Why?
|
| United States | 15 | 2022 | 7114 | 0.270 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2019 | 258 | 0.270 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 3 | 2004 | 11 | 0.270 |
Why?
|
| Ergonomics | 3 | 2022 | 23 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1055 | 0.260 |
Why?
|
| Neoadjuvant Therapy | 3 | 2017 | 376 | 0.250 |
Why?
|
| Melanoma | 1 | 2009 | 471 | 0.230 |
Why?
|
| Patient Selection | 3 | 2013 | 682 | 0.230 |
Why?
|
| Survival Rate | 9 | 2020 | 1899 | 0.230 |
Why?
|
| Male | 21 | 2021 | 42690 | 0.220 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 598 | 0.220 |
Why?
|
| Biopsy, Needle | 2 | 2003 | 231 | 0.220 |
Why?
|
| Treatment Outcome | 7 | 2021 | 8277 | 0.210 |
Why?
|
| Brachytherapy | 2 | 2014 | 120 | 0.210 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2022 | 8 | 0.200 |
Why?
|
| Surgical Oncology | 2 | 2020 | 28 | 0.200 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 201 | 0.190 |
Why?
|
| Age Factors | 6 | 2021 | 1880 | 0.190 |
Why?
|
| Risk Factors | 6 | 2021 | 5562 | 0.190 |
Why?
|
| Hospitals, High-Volume | 1 | 2022 | 38 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 684 | 0.190 |
Why?
|
| Breast | 1 | 2003 | 292 | 0.190 |
Why?
|
| Adrenalectomy | 2 | 2018 | 45 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 841 | 0.180 |
Why?
|
| Length of Stay | 2 | 2022 | 749 | 0.180 |
Why?
|
| Mammaplasty | 1 | 2022 | 110 | 0.180 |
Why?
|
| Thyroid Epithelial Cells | 1 | 2020 | 5 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 569 | 0.170 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2020 | 31 | 0.170 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 46 | 0.160 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 1185 | 0.160 |
Why?
|
| Time Factors | 4 | 2021 | 5358 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 855 | 0.150 |
Why?
|
| Thoracic Wall | 1 | 2018 | 25 | 0.150 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2018 | 55 | 0.150 |
Why?
|
| Biopsy | 2 | 2017 | 1184 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2017 | 476 | 0.150 |
Why?
|
| Survival Analysis | 3 | 2016 | 1497 | 0.140 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 384 | 0.140 |
Why?
|
| Radiation Oncology | 1 | 2019 | 122 | 0.140 |
Why?
|
| Prophylactic Mastectomy | 1 | 2016 | 13 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 120 | 0.130 |
Why?
|
| Neoplasm Grading | 5 | 2016 | 376 | 0.130 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 394 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2020 | 457 | 0.130 |
Why?
|
| Chromatin | 1 | 2018 | 404 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2019 | 584 | 0.120 |
Why?
|
| Mammography | 3 | 2017 | 475 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 168 | 0.120 |
Why?
|
| Risk | 1 | 2016 | 657 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 195 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 521 | 0.120 |
Why?
|
| Prospective Studies | 8 | 2021 | 4329 | 0.110 |
Why?
|
| Young Adult | 6 | 2021 | 6415 | 0.110 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 161 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 365 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1545 | 0.110 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 192 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1169 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 124 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 460 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 260 | 0.100 |
Why?
|
| Thyroid Diseases | 1 | 2013 | 105 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 148 | 0.100 |
Why?
|
| Contraindications | 1 | 2012 | 70 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 173 | 0.100 |
Why?
|
| Workload | 2 | 2022 | 129 | 0.090 |
Why?
|
| Operating Rooms | 2 | 2022 | 125 | 0.090 |
Why?
|
| SEER Program | 3 | 2015 | 205 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 45 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 1732 | 0.080 |
Why?
|
| Radionuclide Imaging | 4 | 2004 | 222 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 2507 | 0.080 |
Why?
|
| Propensity Score | 2 | 2021 | 149 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2009 | 214 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 159 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2009 | 171 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2019 | 872 | 0.070 |
Why?
|
| Adolescent | 5 | 2021 | 9345 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1074 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 848 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 869 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2006 | 126 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3477 | 0.060 |
Why?
|
| Genome, Human | 1 | 2009 | 791 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2003 | 152 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 468 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2022 | 64 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2886 | 0.050 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2003 | 99 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2021 | 50 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 2018 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2022 | 127 | 0.050 |
Why?
|
| Mass Screening | 1 | 2006 | 647 | 0.050 |
Why?
|
| Algorithms | 1 | 2009 | 1913 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2020 | 75 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 310 | 0.040 |
Why?
|
| Hernia, Inguinal | 1 | 2020 | 75 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 91 | 0.040 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 6 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 604 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 107 | 0.040 |
Why?
|
| Conversion to Open Surgery | 1 | 2018 | 11 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 281 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 983 | 0.040 |
Why?
|
| Thyroid Nodule | 1 | 2018 | 62 | 0.040 |
Why?
|
| Hematoxylin | 1 | 1997 | 6 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2018 | 42 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 36 | 0.040 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 1997 | 11 | 0.040 |
Why?
|
| Keratins | 1 | 1997 | 63 | 0.040 |
Why?
|
| Coloring Agents | 1 | 1997 | 65 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 432 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 346 | 0.040 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 83 | 0.030 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2016 | 83 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2020 | 384 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1250 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 297 | 0.030 |
Why?
|
| Selection Bias | 1 | 2014 | 36 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 306 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2013 | 15 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 671 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2014 | 164 | 0.030 |
Why?
|
| Heterozygote | 1 | 2014 | 373 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 199 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1997 | 1801 | 0.030 |
Why?
|
| Urban Population | 1 | 2013 | 225 | 0.030 |
Why?
|
| Illinois | 1 | 2013 | 485 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 345 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2000 | 1131 | 0.020 |
Why?
|
| General Surgery | 1 | 2013 | 236 | 0.020 |
Why?
|
| Hospitals | 1 | 2013 | 303 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2018 | 780 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2769 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 437 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2009 | 35 | 0.020 |
Why?
|
| Postmenopause | 1 | 2009 | 102 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1682 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 2370 | 0.020 |
Why?
|
| Palpation | 1 | 2006 | 18 | 0.020 |
Why?
|
| Community Health Services | 1 | 2006 | 82 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 4169 | 0.010 |
Why?
|
| Ranitidine | 1 | 2000 | 8 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2000 | 91 | 0.010 |
Why?
|
| Premedication | 1 | 2000 | 57 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 301 | 0.010 |
Why?
|
| Physical Examination | 1 | 2000 | 149 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2000 | 293 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2000 | 549 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 343 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2000 | 474 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 741 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2000 | 785 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2000 | 720 | 0.010 |
Why?
|